Specialized facilities, lengthy construction timelines, and workforce constraints could complicate the radiopharmaceutical industry’s path to commercial scale.
The 72,300-square-foot Hamilton, Ontario facility increases the CDMO’s manufacturing capacity more than tenfold and supports clinical through commercial production.
The investment will add suites at the CDMO’s Sunderland facility, increasing the total from six to 10, and expanding commercial active pharmaceutical ingredient production.
